Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 2/20 | 0.32 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.30 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | LSS | P48449 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5743335 | 0.99 | F10 (0.32) | F10ITGB3ITGA2B | |
| SCHEMBL5743460 | 0.93 | F10 (0.31) | F10 | |
| Hydrochloric Acid SCHEMBL5743496 | 0.92 | F10 (0.32) | F10 | |
| SCHEMBL5740694 | 0.92 | F10 (0.36) | F10 | |
| SCHEMBL5757205 | 0.87 | F10 (0.35) | F10ITGB3ITGA2B | |
| SCHEMBL5741415 | 0.86 | F10 (0.37) | F10ITGB3ITGA2B | |
| Hydrochloric Acid SCHEMBL6894610 | 0.84 | F10 (0.33) | F10ITGB3ITGA2BLSS | |
| SCHEMBL5742755 | 0.84 | LSS (0.44) | F10ITGB3ITGA2BLMNALSS | |
| SCHEMBL5744431 | 0.83 | F10 (0.43) | F10LSS | |
| Hydrochloric Acid SCHEMBL5743226 | 0.83 | F10 (0.34) | F10LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7109200-B2 | Carbamate derivatives, process for producing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-09-19 | — | — | US | disclosed |
| EP-1340753-B1 | CARBAMATE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2006-01-11 | — | — | EP | disclosed |
| US-20040038986-A1 | Carbamate derivatives, process for producing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-02-26 | — | — | US | disclosed |
| EP-1340753-A1 | CARBAMATE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2003-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038986-A1 | Carbamate derivatives, process for producing the same and use thereof | CFH, F11, F2 | F10 4/4885ITGB3 1001/4885ITGA2B 882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.